1. Home
  2. CDLR vs HROW Comparison

CDLR vs HROW Comparison

Compare CDLR & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadeler AS

CDLR

Cadeler AS

SELL

Current Price

$21.67

Market Cap

2.1B

Sector

N/A

ML Signal

SELL

HROW

Harrow Inc.

SELL

Current Price

$27.35

Market Cap

1.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CDLR
HROW
Founded
2008
1998
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2023
2008

Fundamental Metrics

Financial Performance
Metric
CDLR
HROW
Price
$21.67
$27.35
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $65.00
AVG Volume (30 Days)
72.7K
★ 623.3K
Earning Date
11-23-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 71.43
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$54.35
$28.59
Revenue Next Year
$37.14
$53.17
P/E Ratio
$7.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.37
$26.96
52 Week High
$30.01
$54.98

Technical Indicators

Market Signals
Indicator
CDLR
HROW
Relative Strength Index (RSI) 38.54 28.20
Support Level $20.96 N/A
Resistance Level $22.21 $35.87
Average True Range (ATR) 0.49 1.32
MACD -0.05 -0.08
Stochastic Oscillator 47.73 12.76

Price Performance

Historical Comparison
CDLR
HROW

About CDLR Cadeler AS

Cadeler AS is an offshore wind installation vessel contractor. It currently operates various offshore jack-up wind installation vessels, with new builds on order. The Group operates within the market for the transportation and installation of offshore wind turbine generators (WTGs) and their foundations. In addition to wind farm installation, its vessels can perform maintenance, decommissioning, and other general construction tasks within the offshore industry. Cadler's customer base consists of offshore wind farm developers, original equipment manufacturers, and various offshore contractors. Geographically, the Group generates maximum revenue from the United States and the rest from the United Kingdom, Taiwan, Germany, Denmark, Poland, and other regions.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: